Professor Wilbert S. Aronow

Professor of Medicine at New York Medical College Director of Cardiology Research at Westchester Medical Center

Biography

Wilbert S. Aronow MD is Professor of Medicine and Director of Cardiology Research at Westchester Medical Center and New York Medical College Valhalla, NY, USA. Dr. Aronow received his MD from Harvard Medical School. He has edited 21 books and is author or co-author of 1,718 papers,  212 book chapters in 116 books, 960 commentaries, 50 Letters to the Editor, and 1204 abstracts and is presenter or co-presenter of 1,582 talks at meetings. Dr. Aronow is a Fellow of the ACC, the AHA, the ACP, the ACCP, the ASPC, the AGS (Founding Fellow of Western Section), and the GSA. He has been a member of 185 editorial boards of medical journals, editor-in-chief of 5 journals, co-editor of 3 journals, deputy editor of 1 journal, executive editor of 2 journals, associate editor for 9 journals, and  guest editor for 7 other medical journals, and has reviewed manuscripts for 444  journals. He has received each year from 2001-2017 an outstanding teacher and researcher award from the medical residents and  from 2001-2022 from the cardiology fellows at Westchester Medical Center/New York Medical College. He has received awards from the Society of Geriatric Cardiology, the Gerontological Society of America, New York Medical College including the 2014 Chancellor’s Research Award and the 2021 excellence in Teaching Dean’s Faculty Award, the F1000 Faculty Member of the Year Award for the Faculty of Cardiovascular Disorders in 2011, and 2013-2021, the Walter Bleifeld Memorial Award for distinguished contributions to clinical research from the International Academy of Cardiology in July, 2010, a Distinguished Fellowship Award from the International Academy of Cardiology in July, 2012, and the Expertscape World Expert in Hypertension  Award in May, 2019.  He has been a member of 4 national guidelines committees including being a coauthor of the 2010 AMDA guidelines for heart failure , co-chair and first author of the 2011 ACC/AHA expert consensus document on hypertension in the elderly, a coauthor of the 2015 AHA/ACC/ASH scientific statement on treatment of hypertension in patients with coronary artery disease, and a coauthor of the 2017 ACC/AHA  guidelines for the management of patients with hypertension. He was a coauthor of a 2015 position paper from the International Lipid Expert Forum. He was a consultant to the American College of Physicians Information and Educational Resource (PIER) on the module of aortic stenosis, a consultant to the American Board of Internal Medicine on hypertension, a member of the Board of Directors of the ASPC, a member of the ACCP Cardiovascular Medicine and Surgery Network Steering Committee, and is a member of the Scientific Executive Committee of the International Academy of Cardiology. He has been a committee member of other professional societies and a consultant to many government agencies. He has mentored 304 cardiology fellows and 669 other trainees plus numerous junior faculty for publications listed on PubMed during his professional career.

 

Expert content

LBPMC Publications

RSS Aronow WS
  • The Significance of Parametric Mapping in Advanced Cardiac Imaging 2024-04-10
    Cardiac magnetic resonance imaging has witnessed a transformative shift with the integration of parametric mapping techniques, such as T1 and T2 mapping and extracellular volume fraction. These techniques play a crucial role in advancing our understanding of cardiac function and structure, providing unique insights into myocardial tissue properties. Native T1 mapping is particularly valuable, correlating […]
    Yeraz Khachatoorian
  • Transcatheter Aortic Valve Implantation for Aortic Regurgitation: A Comprehensive Review 2024-04-03
    Aortic regurgitation (AR), a left-sided valvular heart disease, poses challenges in both diagnosis and treatment. From rheumatic fever to trauma, the vast etiologies of AR can manifest with varying symptoms and disease progression. Nonetheless, without interventions, patients with acute and chronic symptomatic AR have a poor prognosis. This article synthesizes current knowledge on AR management, […]
    Priyanka Gera
  • Shorter Dual Antiplatelet Therapy for Older Adults After Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis 2024-03-28
    CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis of different durations of DAPT for older adults after PCI, an abbreviated DAPT duration was associated with a lower risk of bleeding without any concomitant increase in the risk of MACE or NACE despite the concern for higher-risk coronary anatomy and comorbidities among older adults. This […]
    Dae Yong Park
  • Subcutaneous Furosemide: A Novel to Euvolemia 2024-03-23
    Furoscix, a subcutaneous pH-neutral formulation of furosemide, obtained US Food and Drug Administration approval in October 2022 for adult patients with New York Heart Association class II and class III chronic heart failure. This approval marks an anticipated potential shift in the traditional management of decongestive therapy in chronic heart failure patients from the confines […]
    Ryan Cheikhali
  • Landiolol for Treating Arrhythmias: A State-of-The-Art Review 2024-03-13
    This article provides a state-of-the-art review on landiolol, a medication that was recently submitted for 7 approvals. Focusing on its pharmacology, pharmacokinetics, and pharmacodynamics, the analysis underscores landiolol's unique attributes compared to conventional beta-blockers, particularly esmolol. As a sympatholytic agent, landiolol exhibits a short half-life, high cardioselectivity, and minimal impact on blood pressure, setting it […]
    Muhammad Ghallab
  • Considerations Regarding Management of Heart Failure in Older Adults 2024-02-29
    Understanding noncardiovascular comorbidities and geriatric syndromes in elderly patients with heart failure (HF) is important as the average age of the population increases. Healthcare professionals need to consider these complex dynamics when managing older adults with HF, especially those older than 80. A number of small studies have described associations between HF and major geriatric […]
    Kannayiram Alagiakrishnan
  • Pulmonary Artery Hypertension: Fifty Years Following Pneumonectomy in Infancy 2024-02-27
    Pulmonary hypertension (PH) may be the result of many different pathological processes. PH is a rare but recognized vascular complication following major lung resection. We describe the diagnosis and management of moderate PH resulting more than 50 years in a patient who underwent a total unilateral pneumonectomy in infancy. Unfortunately, patients who undergo pneumonectomy will […]
    Matthew Seplowe
  • COVID-19 and Pulmonary Hypertension: An Interesting Dynamic 2024-02-24
    The dynamic between pulmonary hypertension (PH) and COVID-19 has been under investigation since 2020, early in the pandemic. Although the pathophysiology of PH has been well-studied, new discoveries regarding the multisystemic effects of COVID-19 are still being uncovered. The cardiopulmonary effects of COVID-19 have led investigators to inquire about the interplay between these 2 conditions. […]
    Saam Foroshani
  • Emerging Therapies for Treatment-Resistant Hypertension: A Review of Lorundrostat and Related Selective Aldosterone Synthase Inhibitors 2024-02-15
    The target-hypertension (Target-HTN) trial investigated the efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, as an antihypertensive. Cohort 1 of the trial includes patients with suppressed plasma renin activity and elevated aldosterone levels. Lorundrostat doses of 100 mg and 50 mg daily significantly decreased systolic blood pressure compared to the placebo group. Cohort 2 […]
    Jared M Feldman
  • A Personalized Cell-Based Therapy for Ischemic Heart Failure With Reduced Ejection Fraction: Safety and Feasibility Outcomes of the Roll-In Cohort of the CardiAMP Cell Therapy Trial and Review of Similar Trials 2024-02-14
    CardiAMP Cell Therapy for Heart Failure trial is a prospective, multicenter, randomized, controlled, double-blinded trial that has been granted breakthrough designation by the United States Food and Drug Administration. This trial evaluates clinical outcomes of intramyocardial delivery of a high dose of autologous bone marrow mononuclear cells in chronic postmyocardial infarction heart failure patients. This […]
    Jared M Feldman
  • Low-Carbohydrate/Ketogenic Diet and Coronary Artery Disease: A Brief Review of the Limited Evidence Between Them 2024-02-01
    Nowadays there is a lot of interest among the general population regarding the ketogenic diet (KD) and its health benefits. Most people following this diet have a reduced intake of carbohydrates which gets replaced by calories coming from fat and protein. Even though KD has shown some limited health benefits, there is no consensus on […]
    Josef Kusayev
  • Pharmacological Update and Emerging Treatments of Pulmonary Hypertension 2024-01-31
    Pulmonary hypertension (PH) is defined as elevated pressures in the pulmonary artery and is associated with significant morbidity and mortality. The World Health Organization classifies PH into 5 distinct groups based on underlying etiology, pathology, and modality of treatment. Therapeutic approach may be challenging due to the extensive spectrum of causes and underlying mechanisms mediating […]
    Shazli Khan
  • The Impact of Long COVID-19 on the Cardiovascular System 2024-01-29
    Long coronavirus disease (COVID) is the development or persistence of symptoms after an acute SARS-CoV-2 (COVID-19) infection. Fewer patients are developing acute COVID-19 infections, but patients with long COVID continue to have alarming long-term sequelae. Many cardiac magnetic resonance imaging studies show significant changes in cardiac structure after a COVID-19 infection, suggestive of an increased […]
    Matthew W McMaster
  • Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond 2024-01-24
    INTRODUCTION: Diabetes is a global public health challenge with rising prevalence. This review explores current diabetes understanding, diagnostic and management guidelines, economic impact, and lifestyle modifications as the primary approach.
    Aayushi Sood
  • Endocardial Fibroelastosis: A Comprehensive Review 2024-01-17
    Endocardial fibroelastosis emerged as a challenging clinical phenomenon in the 1940s. It is characterized by an atypical proliferation of fibrous and elastic tissue within the heart and is primarily observed in childhood, occasionally displaying familial inheritance. While the precise cause remains elusive, various factors, including genetic, infectious, metabolic, autoimmune, oncologic, and medication-related influences, appear to […]
    Maryam Barkhordarian
  • Exploring the Intricate Interplay Between Obesity and Atrial Fibrillation: Mechanisms, Management, and Clinical Implications 2024-01-17
    Atrial fibrillation (AF) stands as a prevalent and escalating cardiac arrhythmia in the United States, with obesity emerging as a prominent modifiable risk factor. This article explores the intricate relationship between obesity and AF, delving into the multifaceted pathophysiological mechanisms linking the 2 conditions. Various factors, such as autonomic dysfunction, left atrial stretch, inflammation, and […]
    Swati Chand
  • Low-Dose Colchicine for the Prevention of Cardiovascular Events After Acute Coronary Syndrome 2024-01-08
    Colchicine, an established anti-inflammatory drug, is examined for its potential in mitigating adverse cardiovascular events following acute coronary syndrome (ACS). ACS, primarily triggered by plaque rupture and subsequent thrombosis, is a critical cardiovascular condition. Colchicine's mechanism of action involves inhibiting microtubule activity, leading to immobilization of white blood cells and reducing inflammation. Clinical data from […]
    Priyanka Gera
  • Sacubitril-Valsartan (LCZ696) in the Treatment of Systemic Hypertension: An Updated Review of Neprilysin Inhibition Combined with Angiotensin II Receptor Blockade 2024-01-03
    Sacubitril-valsartan (LCZ696) has been demonstrated to be a highly effective treatment for heart failure with preserved ejection fraction since its Food and Drug Administration approval in 2015, and a growing body of evidence suggests its emergence as a hypertensive medication. It acts as an inhibitor of both neprilysin and the renin-angiotensin-aldosterone system, approaching the control […]
    Miriam E Katz
  • The Role of Palliative Care in Cardiovascular Disease 2024-01-03
    The American Heart Association has recommended that palliative care be integrated into the care of all patients with advanced cardiac illnesses. Notwithstanding, the number of patients receiving specialist palliative intervention worldwide remains extremely small. This review examines the nature of palliative care and what is known about its delivery to patients with cardiac illness. Most […]
    John Arthur McClung
  • Risk factors modification in atrial fibrillation: a brief review 2023-12-18
    INTRODUCTION: Atrial fibrillation (AF) is a supraventricular arrhythmia characterized by fibrillatory waves in the atria with an irregular ventricular rhythm. It is the most common arrhythmia treated in clinical practice. AF is associated with approximately five-fold increase in risk of cerebrovascular accident (stroke) and two-fold increase in cognitive dysfunction and all-cause mortality.
    Sukhbir Randhawa